These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24134649)

  • 1. Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study.
    Shigehara K; Koh E; Sakamoto J; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Maeda Y; Kadono Y; Konaka H; Mizokami A; Nakashima T; Namiki M
    Aging Male; 2014 Mar; 17(1):51-6. PubMed ID: 24134649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
    Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
    Wada N; Hashidume K; Tamaki G; Kita M; Iwata T; Matsumoto S; Kakizaki H
    Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
    Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
    Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
    Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
    Shigehara K; Miyagi T; Nakashima T; Izumi K; Kitagawa Y; Mizokami A; Koh E; Shimamura M; Namiki M
    Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.
    Wada N; Hashizume K; Matsumoto S; Kakizaki H
    Aging Male; 2016; 19(1):12-4. PubMed ID: 26225793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study.
    Choo MS; Song M; Kim JH; Lee KS; Kim JC; Kim SW; Yang SK; Lee JG; Lee JZ; Kim DK; Park WH; Kim KD; Na YG; Kwon DD; Paick JS
    Urology; 2014 Apr; 83(4):875-81. PubMed ID: 24529580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
    Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
    Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.
    Cho HJ; Shin SC; Seo DY; Cho JM; Kang JY; Yoo TK; Yu JH; Sung LH; Moon HS
    Int J Clin Pract; 2014 Apr; 68(4):471-7. PubMed ID: 24471868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).
    Yamanishi T; Asakura H; Seki N; Tokunaga S
    Low Urin Tract Symptoms; 2019 May; 11(3):115-121. PubMed ID: 30358116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.